MedTrace Logo

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

NCT02581553 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2016-12-19

No results posted yet for this study

Summary

This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.

Conditions

  • Healthy

Interventions

DRUG

lesinurad/allopurinol 200/300 FDC tablets

DRUG

lesinurad 200 mg

DRUG

allopurinol 300 mg

DRUG

lesinurad/allopurinol 200/200 FDC tablets

DRUG

allopurinol 200 mg

Sponsors & Collaborators

  • Ardea Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • N. Bhakta · Ardea Biosciences, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-07-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02581553 on ClinicalTrials.gov